Purpose: To investigate the ability of extracellular vesicles (EVs) to deliver oxaliplatin to
epidermal growth factor receptor (EGFR+) colorectal cancer cells and increase oxaliplatin's …

Abstract Oxaliplatin (L-OH), a platinum derivative with good tolerability is currently combined
with Cetuximab (CTX), a monoclonal antibody (mAb), for the treatment of certain (wild-type …

Colorectal cancer remains one of the main causes of cancer-related deaths worldwide.
Although numerous nanomedicine formulations have been developed to tackle the disease …

Despite the numerous advances in target therapy for the treatment of colorectal cancer,
aggressive colorectal cancer remains an incurable disease whose negative modulation of …

The purpose of this study was to investigate the effect of chemoresistant cancer-associated
fibroblasts (R-CAFs) against cisplatin (DDP) on colorectal cancer (CRC) progression. First …

Colorectal cancer (CRC) is one of the oncological malignancies with the highest incidence
and mortality rates. The dominant cause for such a high death rate is at large associated to …

METHODS: EVs were isolated from HepG2 cells and further loaded with the
chemotherapeutic drug doxorubicin (Dox). Furthermore, we coated the Dox-loaded EVs …

Background Butyrate-resistant (BR) cells play an important role in acquiring
chemoresistance in colorectal cancer (CRC). Our previous study demonstrated that BR CRC …

Cisplatin is a first-line clinical agent used for treating solid tumors. Cisplatin damages the
DNA of tumor cells and induces the production of high levels of reactive oxygen species to …

Simple Summary Almost all cell types produce extracellular vesicles that, according to their
size, subcellular origin and release pathways, are mainly categorized as exosomes …